289 related articles for article (PubMed ID: 38001899)
1. The Multifaceted Role of Osteopontin in Prostate Pathologies.
Silver SV; Popovics P
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001899
[TBL] [Abstract][Full Text] [Related]
2. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.
Popovics P; Awadallah WN; Kohrt SE; Case TC; Miller NL; Ricke EA; Huang W; Ramirez-Solano M; Liu Q; Vezina CM; Matusik RJ; Ricke WA; Grabowska MM
Prostate; 2020 Jul; 80(10):731-741. PubMed ID: 32356572
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary approach to prostatitis.
Magri V; Boltri M; Cai T; Colombo R; Cuzzocrea S; De Visschere P; Giuberti R; Granatieri CM; Latino MA; Larganà G; Leli C; Maierna G; Marchese V; Massa E; Matteelli A; Montanari E; Morgia G; Naber KG; Papadouli V; Perletti G; Rekleiti N; Russo GI; Sensini A; Stamatiou K; Trinchieri A; Wagenlehner FME
Arch Ital Urol Androl; 2019 Jan; 90(4):227-248. PubMed ID: 30655633
[TBL] [Abstract][Full Text] [Related]
5. Steroid hormone imbalance drives macrophage infiltration and Spp1/osteopontin
Popovics P; Skalitzky KO; Schroeder E; Jain A; Silver SV; Van Fritz F; Uchtmann KS; Vezina CM; Ricke WA
J Pathol; 2023 Jun; 260(2):177-189. PubMed ID: 36825524
[TBL] [Abstract][Full Text] [Related]
6. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of osteopontin expression in human prostate cancer.
Forootan SS; Foster CS; Aachi VR; Adamson J; Smith PH; Lin K; Ke Y
Int J Cancer; 2006 May; 118(9):2255-61. PubMed ID: 16331611
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin expression in prostate cancer and benign prostatic hyperplasia.
Tozawa K; Yamada Y; Kawai N; Okamura T; Ueda K; Kohri K
Urol Int; 1999; 62(3):155-8. PubMed ID: 10529666
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin Deficiency Ameliorates Prostatic Fibrosis and Inflammation.
Popovics P; Jain A; Skalitzky KO; Schroeder E; Ruetten H; Cadena M; Uchtmann KS; Vezina CM; Ricke WA
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830342
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study.
Kaya E; Ozgok Y; Zor M; Eken A; Bedir S; Erdem O; Ebiloglu T; Ergin G
Adv Clin Exp Med; 2017 Oct; 26(7):1095-1099. PubMed ID: 29211357
[TBL] [Abstract][Full Text] [Related]
11. Prostate Infiltration by Treg and Th17 Cells as an Immune Response to
Radej S; Szewc M; Maciejewski R
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012113
[TBL] [Abstract][Full Text] [Related]
12. Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases.
Bleeker J; Wang ZA
Front Mol Biosci; 2022; 9():898871. PubMed ID: 35865005
[TBL] [Abstract][Full Text] [Related]
13. Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in prostatic disorders in dogs.
Weinekötter J; Gurtner C; Protschka M; von Bomhard W; Böttcher D; Alber G; Kiefer I; Steiner JM; Seeger J; Heilmann RM
BMC Vet Res; 2023 Nov; 19(1):234. PubMed ID: 37946179
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory response to Trichomonas vaginalis in the pathogenesis of prostatitis and benign prostatic hyperplasia.
Han IH; Kim JH; Ryu JS
Parasites Hosts Dis; 2023 Feb; 61(1):2-14. PubMed ID: 37170459
[TBL] [Abstract][Full Text] [Related]
15. The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.
Oseni SO; Naar C; Pavlović M; Asghar W; Hartmann JX; Fields GB; Esiobu N; Kumi-Diaka J
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370720
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin is a tumor autoantigen in prostate cancer patients.
Tilli TM; Silva EA; Matos LC; Faget DV; Dias BF; Vasconcelos JS; Yokosaki Y; Gimba ER
Oncol Lett; 2011 Jan; 2(1):109-114. PubMed ID: 22870138
[TBL] [Abstract][Full Text] [Related]
17. [Zinc levels in prostatic fluid of patients with prostate pathologies].
Gómez Y; Arocha F; Espinoza F; Fernández D; Vásquez A; Granadillo V
Invest Clin; 2007 Sep; 48(3):287-94. PubMed ID: 17853788
[TBL] [Abstract][Full Text] [Related]
18. The role of prostatic inflammation in the development and progression of benign and malignant diseases.
Gandaglia G; Zaffuto E; Fossati N; Cucchiara V; Mirone V; Montorsi F; Briganti A
Curr Opin Urol; 2017 Mar; 27(2):99-106. PubMed ID: 27906778
[TBL] [Abstract][Full Text] [Related]
19. The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions.
Flores-Fraile MC; Padilla-Fernández BY; Valverde-Martínez S; Marquez-Sanchez M; García-Cenador MB; Lorenzo-Gómez MF; Flores-Fraile J
J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33114134
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis.
Yu A; Guo K; Qin Q; Xing C; Zu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 33635319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
